iPPI-DB

Inhibitors of Protein-Protein Interaction Database

Compound 173

Identifiers

  • Canonical SMILES: 
    OC(=O)CCCCN1c2ccc(I)cc2C(=O)N([C@@H](C(O)=O)c2ccc(Cl)cc2)[C@@H](c2ccc(Cl)cc2)C1=O
  • IUPAC name: 
    5-[4-[carboxy-(4-chlorophenyl)methyl]-3-(4-chlorophenyl)-7-iodo-2,5-dioxo-3H-1,4-benzodiazepin-1-yl]pentanoic acid
  • InChi: 
    InChI=1S/C28H23Cl2IN2O6/c29-18-8-4-16(5-9-18)24-27(37)32(14-2-1-3-23(34)35)22-13-12-20(31)15-21(22)26(36)33(24)25(28(38)39)17-6-10-19(30)11-7-17/h4-13,15,24-25H,1-3,14H2,(H,34,35)(H,38,39)/t24-,25+/m0/s1
  • InChiKey: 
    JFDPWVMFHFOLFW-LOSJGSFVSA-N

External links


168318326
10793053

External search

Bibliography (1)

Publication Name
Parks DJ, LaFrance LV, Calvo RR, Milkiewicz KL, Marugán JJ, Raboisson P, Schubert C, Koblish HK, Zhao S, Franks CF, Lattanze J, Carver TE, Cummings MD, Maguire D, Grasberger BL, Maroney AC, Lu T. . Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Bioorganic & medicinal chemistry letters. 13

Pharmacological data

Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 2 0 0

Targets

PPI family Best activity Diseases MMoA
MDM2-Like / P53 6.29 cancer Inhibition
Physicochemical filters
Descriptor Lipinski's RO5 Veber Pfizer's 3/75
Compliance
MW 680.00 g/mol
HBA 8
HBD 2
HBA + HBD 10
AlogP 6.01
TPSA 115.22
RB 9
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 1 2 0 0
Pharmacological data
Bibliography Name Target Competition Assay type Assay name Cell line Activity type Activity
16600594 13 MDM2
Q00987
Biochemical assay Fluorescence Polarization pIC50 (half maximal inhibitory concentration, -log10) 6.29
16600594 13 MDM2
Q00987
Cellular assay Proliferation assay MCF7 mammary carcinoma cells pIC50 (half maximal inhibitory concentration, -log10) 4.42
16600594 13 MDM2
Q00987
Cellular assay Proliferation assay MDA MB321 mammary carcinoma cells pIC50 (half maximal inhibitory concentration, -log10) 3.89
Ta Structure Name Drugbank ID
0.5085 4-[(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)amino]-4-oxobutanoic acid DB08581
0.5056 Bentiromide DB00522
0.4973 N-(4-bromo-2-{[(3R,5S)-3,5-dimethylpiperidin-1-yl]carbonyl}phenyl)-4-morpholin-4-yl-4-oxobutanamide DB08582
0.4947 Ombitasvir DB09296
0.4892 Delparantag DB12955
0.4885 [(2S)-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-2-yl]acetic acid DB08717
0.4872 SLV-334 DB15356
0.4854 Balicatib DB12239
0.4850 4-chloro-N-(3-methoxypropyl)-N-[(3S)-1-(2-phenylethyl)piperidin-3-yl]benzamide DB08344
0.4839 Benazeprilat DB14125
0.4800 Dexloxiglumide DB04856
0.4795 OPC-28326 DB05461
0.4764 2-{[4-(2-Acetylamino-2-pentylcarbamoyl-ethyl)-naphthalen-1-YL]-oxalyl-amino}-benzoic acid DB01820
0.4746 Virginiamycin S1 DB04805
0.4746 Fominoben DB08968